While biologics are emerging as the standard of care for rheumatoid arthritis (RA), they continue to be compared to methotrexate frequently in health technology assessments (HTAs). We examined comparators used by HTA agencies for RA drugs, both tumor necrosis factor (TNF) drugs and disease-modifying, anti-rheumatic drugs (DMARDs), and compared each drug’s HTA decision to its European label. We also assessed the change in comparator categories for RA drugs over time.
The product team at Context Matters is always working on ways to improve our customers’ subscriptions. This year alone we’ve published new data from over 2,000 HTA reviews and regulatory labels and deployed over 130 updates to our application and data model. Today, I’d like to highlight some of the capabilities our customers can now use and provide a preview of what we’re working on this spring.